The U.S. Food and Drug Administration granted emergency use authorization to Yale School of Public Health’s saliva test to detect Covid-19, after a trial on National Basketball Association players and staff.
Passage Bio’s first attempt to develop a GM1 gangliosidosis gene therapy treatment ran into a roadblock in the form of a clinical hold.
Veru Inc. is developing a dual anti-inflammatory/antiviral medication to combat severe Covid-19 infections.
Researchers at the University of California, San Francisco (UCSF) synthesized a molecule inspired by llama antibodies called nanobodies that could neutralize SARS-CoV-2, the virus that causes Covid-19.
With billions of doses of Covid-19 expected to be available by year’s end, and a global population of 7.8 billion, public health officials are scrambling to deliver the vaccines in ways that are equitable and effective. The challenge is about more than having a vaccine, and more than delivering it, public health experts at Johns Hopkins Medical School explained during a media briefing.
A review of recently published scientific studies includes a look at the potential of using flu and pneumonia vaccines to decrease the risk of developing Alzheimer’s disease.
A study published in the journal Cell Stem Cell revealed how aging can cause lung regeneration to go awry, which can potentially lead to lung cancer and other diseases.
Moderna Inc. and Pfizer Inc. launched two 30,000-subject trials of Covid-19 vaccines that could clear the way for regulatory approval and widespread use by the end of 2020.
European efforts to secure potential COVID-19 vaccines from Pfizer, Sanofi and Johnson & Johnson are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.
The University of Oxford suggested that the end of 2020 is possible for the availability of a Covid-19 vaccine candidate being developed with AstraZeneca, but expressed caution about the timeline.